Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.57 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498840 | 1.00 | KDM4E (0.65) | KDM4EMEN1KMT2AGPR84PTPN5 | |
| SCHEMBL1224223 | 0.85 | TP53 (0.60) | KDM4EMEN1KMT2AGPR84NR4A2 | |
| SCHEMBL4208833 | 0.85 | L3MBTL1 (0.63) | KDM4EMEN1KMT2AGPR84PTPN5 | |
| SCHEMBL23084313 | 0.84 | KDM4E (0.59) | KDM4EMEN1KMT2AGPR84PTPN5 | |
| SCHEMBL21244773 | 0.84 | KDM4E (0.49) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL23084537 | 0.83 | MAPT (0.50) | KDM4EMEN1KMT2ANR4A2MAPT | |
| SCHEMBL15747713 | 0.82 | CDC25A (0.59) | KDM4ENR4A2MAPTALDH1A1GAA | |
| SCHEMBL2504591 | 0.82 | KDM4E (0.67) | KDM4EMEN1KMT2AGPR84MAPT | |
| SCHEMBL28836620 | 0.82 | CDC25A (0.52) | KDM4ENR4A2MAPTALDH1A1GAA | |
| SCHEMBL341492 | 0.82 | GPR84 (0.62) | KDM4EMEN1KMT2AGPR84PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442026-A1 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | claimed |
| WO-2003040110-A1 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | claimed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12139459-B2 | Enhancer of fertilization function of sperm | TOHOKU UNIVERSITY (JP) | 2024-11-12 | — | — | US | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220106270-A1 | ENHANCER OF FERTILIZATION FUNCTION OF SPERM | KAKE EDUCATIONAL INSTITUTION (JP) | 2022-04-07 | — | — | US | disclosed |
| CN-113292557-B | Pyridopyrimidinone mesoion derivative containing indole unit and preparation method and application thereof | 贵州大学 | 2022-02-11 | — | — | CN | disclosed |
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | QUANTUM GENOMICS (FR) | 2021-12-07 | — | — | US | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-5747236-A | FRAGMENTABLE ELECTRON DONOR | EASTMAN KODAK COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0786691-A1 | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity | EASTMAN KODAK COMPANY (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5556874-A | ENZYME INHIBITORS AS ANTICARCINOGENIC AGENTS | WARNER LAMBERT COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| US-5464861-A | Anticarcinogenic agents | WARNER-LAMBERT (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0654024-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-05-24 | — | — | EP | disclosed |
| EP-0345808-B1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-01-11 | — | — | EP | disclosed |
| WO-1994003427-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
| US-4954502-A | Antidepressants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0345808-A1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | Bristol-Myers Squibb Company (US) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | ANPEP, DNPEP, ENPEP | KDM4E 3698/4885MEN1 1271/4885KMT2A 3733/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | KDM4E 1603/4885MEN1 2648/4885KMT2A 2907/4885 |
| US-12139459-B2 | Enhancer of fertilization function of sperm | CATSPER1, NASP, ZP1 | KDM4E 2497/4885MEN1 4153/4885KMT2A 3412/4885 |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | KDM4E 4657/4885MEN1 1339/4885KMT2A 4378/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | KDM4E 1634/4885MEN1 1031/4885KMT2A 2966/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | KDM4E 1634/4885MEN1 1031/4885KMT2A 2966/4885 |
| US-20220106270-A1 | ENHANCER OF FERTILIZATION FUNCTION OF SPERM | CATSPER1, NASP, ZP1 | KDM4E 2497/4885MEN1 4153/4885KMT2A 3412/4885 |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | KDM4E 1634/4885MEN1 1031/4885KMT2A 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.